NI201900092A - Combinación farmacéutica que comprende ponesimod - Google Patents

Combinación farmacéutica que comprende ponesimod

Info

Publication number
NI201900092A
NI201900092A NI201900092A NI201900092A NI201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A NI 201900092 A NI201900092 A NI 201900092A
Authority
NI
Nicaragua
Prior art keywords
ponesimod
pharmaceutical combination
combination including
active ingredient
teriflunomide
Prior art date
Application number
NI201900092A
Other languages
English (en)
Inventor
Clozel Martine
Ágainé Csongor Éva
Pouzol Laetitia
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NI201900092A publication Critical patent/NI201900092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se relaciona con una combinación farmacéutica que comprende un primer ingrediente activo que es ponesimod y un segundo ingrediente activo que se selecciona del grupo que consiste en teriflunomida y leflunomida.
NI201900092A 2017-03-14 2019-09-11 Combinación farmacéutica que comprende ponesimod NI201900092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (1)

Publication Number Publication Date
NI201900092A true NI201900092A (es) 2020-03-11

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900092A NI201900092A (es) 2017-03-14 2019-09-11 Combinación farmacéutica que comprende ponesimod

Country Status (24)

Country Link
US (2) US11723896B2 (es)
EP (1) EP3595657A1 (es)
JP (2) JP7281406B2 (es)
KR (1) KR102574562B1 (es)
CN (1) CN110381942B (es)
AU (2) AU2018233109B2 (es)
BR (1) BR112019018894A2 (es)
CA (1) CA3056301A1 (es)
CL (1) CL2019002525A1 (es)
CO (1) CO2019008510A2 (es)
CR (1) CR20190464A (es)
DO (1) DOP2019000257A (es)
EA (1) EA201992117A1 (es)
EC (1) ECSP19073317A (es)
IL (1) IL269239B2 (es)
JO (1) JOP20190207A1 (es)
MA (1) MA49822A (es)
MX (1) MX2019010874A (es)
NI (1) NI201900092A (es)
PE (1) PE20191489A1 (es)
PH (1) PH12019502110A1 (es)
SG (1) SG11201907308UA (es)
UA (1) UA125756C2 (es)
WO (1) WO2018167030A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
ES2352555T3 (es) 2003-11-21 2011-02-21 Actelion Pharmaceuticals Ltd. Derivados de 5-(benc-(z)-iliden)tiazolidin-4-ona como agentes inmunosupresores.
CN101043883A (zh) 2004-10-19 2007-09-26 安万特药物公司 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
AU2007323042B2 (en) 2006-11-23 2012-12-20 Actelion Pharmaceuticals Ltd New process for the preparation of 2-imino-thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
AR070842A1 (es) 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
NZ617025A (en) 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EP2885266B1 (en) 2012-08-17 2020-03-18 Actelion Pharmaceuticals Ltd Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
UA122064C2 (uk) 2014-12-11 2020-09-10 Актеліон Фармасьютікалз Лтд Схема дозування для селективного агоніста рецептора s1p1
AU2016280276A1 (en) 2015-06-18 2017-12-07 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions

Also Published As

Publication number Publication date
JP7281406B2 (ja) 2023-05-25
CO2019008510A2 (es) 2019-10-21
BR112019018894A2 (pt) 2020-04-14
WO2018167030A1 (en) 2018-09-20
CA3056301A1 (en) 2018-09-20
CR20190464A (es) 2019-11-26
KR20190122716A (ko) 2019-10-30
AU2018233109B2 (en) 2023-09-28
DOP2019000257A (es) 2020-09-15
US20200069655A1 (en) 2020-03-05
US11723896B2 (en) 2023-08-15
KR102574562B1 (ko) 2023-09-04
ECSP19073317A (es) 2019-11-30
EP3595657A1 (en) 2020-01-22
IL269239B2 (en) 2023-07-01
MA49822A (fr) 2020-06-17
CN110381942A (zh) 2019-10-25
IL269239B1 (en) 2023-03-01
MX2019010874A (es) 2019-12-11
CN110381942B (zh) 2022-12-27
PH12019502110A1 (en) 2020-03-16
AU2023274118A1 (en) 2023-12-21
JOP20190207A1 (ar) 2019-09-10
IL269239A (en) 2019-11-28
JP2020510045A (ja) 2020-04-02
EA201992117A1 (ru) 2020-02-17
SG11201907308UA (en) 2019-09-27
UA125756C2 (uk) 2022-06-01
CL2019002525A1 (es) 2020-02-07
US20240139161A1 (en) 2024-05-02
PE20191489A1 (es) 2019-10-21
JP2023030091A (ja) 2023-03-07
AU2018233109A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
ECSP19073317A (es) Combinación farmacéutica que comprende ponesimod
CR20170099A (es) Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
BR112017004948A2 (pt) formulação farmacêutica.
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2018000282A1 (es) Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol
CL2019000144A1 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos.
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
EA201890477A1 (ru) Инкапсулированная композиция финголимода
UY36273A (es) Composicion para el tratamiento de neuropatías y del dolor neuropático
EA201990162A1 (ru) Фармацевтические композиции
EA201792093A1 (ru) 2-тиопиримидиноны
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
BR112017008746A2 (pt) composição herbicida que contém penoxsulam
FR3019047B1 (fr) Diffuseur d'agent parfumant et/ou assainissant active par retournement.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CL2016003273A1 (es) Composiciones antimicrobianas con agentes efervescentes
TR201618030T2 (tr) Tadı düzeltilmiş parasetamol formülasyonları.
CO2019004796A2 (es) Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina